Aspen Neuroscience, Inc. (ASPE): who owns it and who trades it
As of Nov 9, 2026, ASPE insiders reported 4 purchases worth $35M in the last 12 months. The largest buyer was ARCH Venture Fund X, L.P. (10% owner), with $20M.
Latest filing Nov 9, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, ASPE insiders reported $35M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Orbimed Advisors Llc +1 | Director | Purchase | 1.00M | $15.00 | $15M | Form 4 |
| Nov 2, 2026 | ARCH Venture Fund X, L.P. +8 | 10% owner | Purchase | 66,666 | $15.00 | $1000K | Form 4 |
| Nov 2, 2026 | ARCH Venture Fund X, L.P. +8 | 10% owner | Purchase | 66,667 | $15.00 | $1M | Form 4 |
| Nov 2, 2026 | ARCH Venture Fund X, L.P. +8 | 10% owner | Purchase | 1.20M | $15.00 | $18M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| ARCH Venture Fund X, L.P. | 10% owner | $20M | – | Nov 2, 2026 |
| Orbimed Advisors Llc | Director, 10% owner | $15M | – | Nov 2, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
Aspen Neuroscience company events
Aspen Neuroscience filed 1 report on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 2, 2026.
- Nov 2, 2026AnnouncementThe Company completed the IPO of 9,375,000 shares of the Company’s common stock, par value $0.0001 per share, at a price to the public of $15.00 per share. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 12 filings named ASPE in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 9, 2026 | ARCH Venture Fund X, L.P. | 13D | 12.9% |
| Nov 9, 2026 | ARCH Venture Fund X, L.P. | 13D | 12.9% |
| Nov 9, 2026 | Frazier Life Sciences X, L.P. | 13G | 5.8% |
| Nov 9, 2026 | Frazier Life Sciences X, L.P. | 13G | 5.8% |
| Nov 6, 2026 | ORBIMED ADVISORS LLC | 13D | 12.3% |
| Nov 6, 2026 | ORBIMED ADVISORS LLC | 13D | 12.3% |
| Nov 6, 2026 | FMR LLC | 13G | 11.2% |
| Nov 6, 2026 | GILEAD SCIENCES, INC. | 13G | 9.9% |
| Nov 6, 2026 | FMR LLC | 13G | 11.2% |
| Nov 6, 2026 | GILEAD SCIENCES, INC. | 13G | 9.9% |
| Nov 3, 2026 | Qatar Investment Authority | 13G | 6.7% |
| Nov 3, 2026 | Qatar Investment Authority | 13G | 6.7% |
Questions about Aspen Neuroscience, Inc. (ASPE) stock
Are ASPE insiders buying or selling?
In the last 12 months, ASPE insiders reported 4 open-market purchases worth $35M and no sales. The latest trade was on Nov 2, 2026. See every trade.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.